|
|
在研机构- |
|
在研适应症- |
|
最高研发阶段撤市 |
|
首次获批日期2003-11-25 |
Phase III Study of the Comparison of Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer. A One Year Randomised, Open Label, Multi-Centre Phase III Trial.
To compare the safety of efficacy of abarelix versus goserelin plus bicalutamide in patients with advanced or metastatic prostate cancer.
100 项与 Speciality European Pharma Ltd. /Private Group/ 相关的临床结果
0 项与 Speciality European Pharma Ltd. /Private Group/ 相关的专利(医药)
100 项与 Speciality European Pharma Ltd. /Private Group/ 相关的药物交易
100 项与 Speciality European Pharma Ltd. /Private Group/ 相关的转化医学